Next Article in Journal
Translational Regulators in Pulmonary Fibrosis: MicroRNAs, Long Non-Coding RNAs, and Transcript Modifications
Previous Article in Journal
PPAR-γ in Melanoma and Immune Cells: Insights into Disease Pathogenesis and Therapeutic Implications
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 14
Issue 7
10.3390/cells14070535
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Cells 2021, 10(5), 987.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987

by
Uly Sumarni
,
Ulrich Reidel
and
Jürgen Eberle
*
Apoptosis Regulation in Skin Cancer, Skin Cancer Center Charité, Department of Dermatology Venerology und Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany
*
Author to whom correspondence should be addressed.
Cells 2025, 14(7), 535; https://doi.org/10.3390/cells14070535
Submission received: 18 December 2024 / Accepted: 21 January 2025 / Published: 3 April 2025
Browse Figure
Versions Notes
In the original publication [1], there was a mistake in Figure 6 as published. The GAPDH panels in Figures 5f and 6b,f were the same due to the accidental swapping of the blots. The corrected Figure 6 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Sumarni, U.; Reidel, U.; Eberle, J. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987. [Google Scholar] [CrossRef]
Cells 14 00535 g006
Figure 6. Role of PKCδ in PEP005-induced apoptosis. (a) Effects of PEP005 (50 nM, 24 h) on PKCδ proform (78 kDa) were investigated in four CTCL cell lines. (b,c) Lacking effects of QVD-Oph (QVD, 5 µM, (b)) and vitamin E (VitE, 1 mM, (c)) on PEP005-induced downregulation of PKCδ proform are shown (50 nM, 24 h). (d,e) Inhibition of PEP005-induced apoptosis (d) and restoration of cell viability (e) by Bis-1 in HH and HuT-78. Cells were treated for 24 h with PEP005 (50 nM) and/or Bis-1 (HH, 1 µM; HuT-78, 0.25 µM). (f) Inhibition of PEP005-mediated caspase-3, -8, and -9 processing through Bis-1, as investigated by Western blotting in HH and HuT-78. Cells were treated for 24 h with 50 nM PEP005; Bis-1 was used at 1 (HH) and 0.25 µM (HuT-78), respectively). (g,h) Antagonistic effects of Bis-1 on PEP005-mediated loss of MMP (g) and on PEP005-induced ROS production (h) in cell line HuT-78 (Time: 24 h; PEP005: 50 nM; Bis-1: 0.25 µM). (a–c,f) For Western blotting, 30 µg of each protein extract was loaded per lane, and blots were probed with antibodies for PKCδ proform (78 kDa), cleaved caspase-3 (21, 19, 17 kDa), caspase-8 (proform, 57 kDa; cleavage products, 43/41 kDa) and caspase-9 (cleavage product, 35 kDa). GAPDH (37 kDa) was used as loading control. For Western blots, two independent series of protein extracts revealed highly comparable results. (d,e,g,h) Mean values of triplicates ± SDs of representative experiments are shown. At least two independent experiments showed highly comparable results. Statistical significance was calculated from all values (at least 6) and is indicated for combination-treated cells vs. PEP005-treated cells (* p < 0.05).
Figure 6. Role of PKCδ in PEP005-induced apoptosis. (a) Effects of PEP005 (50 nM, 24 h) on PKCδ proform (78 kDa) were investigated in four CTCL cell lines. (b,c) Lacking effects of QVD-Oph (QVD, 5 µM, (b)) and vitamin E (VitE, 1 mM, (c)) on PEP005-induced downregulation of PKCδ proform are shown (50 nM, 24 h). (d,e) Inhibition of PEP005-induced apoptosis (d) and restoration of cell viability (e) by Bis-1 in HH and HuT-78. Cells were treated for 24 h with PEP005 (50 nM) and/or Bis-1 (HH, 1 µM; HuT-78, 0.25 µM). (f) Inhibition of PEP005-mediated caspase-3, -8, and -9 processing through Bis-1, as investigated by Western blotting in HH and HuT-78. Cells were treated for 24 h with 50 nM PEP005; Bis-1 was used at 1 (HH) and 0.25 µM (HuT-78), respectively). (g,h) Antagonistic effects of Bis-1 on PEP005-mediated loss of MMP (g) and on PEP005-induced ROS production (h) in cell line HuT-78 (Time: 24 h; PEP005: 50 nM; Bis-1: 0.25 µM). (a–c,f) For Western blotting, 30 µg of each protein extract was loaded per lane, and blots were probed with antibodies for PKCδ proform (78 kDa), cleaved caspase-3 (21, 19, 17 kDa), caspase-8 (proform, 57 kDa; cleavage products, 43/41 kDa) and caspase-9 (cleavage product, 35 kDa). GAPDH (37 kDa) was used as loading control. For Western blots, two independent series of protein extracts revealed highly comparable results. (d,e,g,h) Mean values of triplicates ± SDs of representative experiments are shown. At least two independent experiments showed highly comparable results. Statistical significance was calculated from all values (at least 6) and is indicated for combination-treated cells vs. PEP005-treated cells (* p < 0.05).
Cells 14 00535 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sumarni, U.; Reidel, U.; Eberle, J. Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987. Cells 2025, 14, 535. https://doi.org/10.3390/cells14070535

AMA Style

Sumarni U, Reidel U, Eberle J. Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987. Cells. 2025; 14(7):535. https://doi.org/10.3390/cells14070535

Chicago/Turabian Style

Sumarni, Uly, Ulrich Reidel, and Jürgen Eberle. 2025. "Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987" Cells 14, no. 7: 535. https://doi.org/10.3390/cells14070535

APA Style

Sumarni, U., Reidel, U., & Eberle, J. (2025). Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987. Cells, 14(7), 535. https://doi.org/10.3390/cells14070535

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop